Lineage Cell Therapeutics Inc Dossier - Source-backed chat

Lineage Cell Therapeutics Inc

LCTXNYSE

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.37

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $0.90Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $228.7M

Enterprise Value $193.7M

Shares Outstanding 264.4M diluted

Next Earnings Date5 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Lineage Cell Therapeutics is a clinical-stage biotechnology company uniquely positioned in the regenerative medicine space. Its proprietary AlloSCOPE platform enables the scalable, cGMP-compliant manufacture of specialized human cells from pluripotent stem cell lines. The company's investment thesis is anchored by its high-profile, $670 million collaboration with Roche and Genentech for its lead asset, OpRegen, which targets dry age-related macular degeneration (AMD) with geographic atrophy. This partnership provides strong scientific validation and substantial non-dilutive funding potential. With a cash runway extending into Q2 2028 and a diversified pipeline addressing multi-billion dollar markets in neurology, ophthalmology, and otology, Lineage offers a compelling high-risk, high-reward opportunity for biotech investors.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets6 analysts · as of 18 Aug 2026

Low · most bearish analyst$3.00

Mean target$5.50

High · most bullish analyst$9.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$3.0015%

The bear case is triggered by clinical setbacks or safety concerns in the OpRegen or OPC1 programs, or a slower-than-expected development timeline by partner Genentech. High R&D expenses and lack of near-term milestone payments could accelerate cash burn, forcing dilutive equity raises before the Q2 2028 runway limit is reached.

Base CaseCentral scenario

$5.5060%

Matches the consensus mean

The base case projects steady progress of the OpRegen program with moderate milestone inflows from Roche/Genentech. OPC1 continues its clinical path with incremental data readouts, and the company maintains its cash runway into 2028 through disciplined R&D spending. Valuation is supported by the consensus analyst target reflecting the intrinsic value of the platform and lead assets.

Bull CaseUpside scenario

$9.0025%

The bull case assumes rapid clinical advancement of OpRegen under Roche/Genentech, triggering significant milestone payments. Concurrently, OPC1 demonstrates robust efficacy in spinal cord injury trials, and preclinical programs like ReSonance (ANP1) and ILT1 (Type 1 Diabetes) successfully transition to clinical stages. Scalable manufacturing efficiencies from the AlloSCOPE platform keep operating expenses controlled, leading to a highly favorable valuation re-rating.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong validation and financial backing through the $670 million Roche/Genentech collaboration for OpRegen.
Proprietary AlloSCOPE manufacturing platform capable of producing off-the-shelf, clinical-grade cell therapies at scale.
Robust cash position of $53.4 million providing a runway into Q2 2028, reducing near-term dilution risk.
Diversified pipeline targeting high-unmet-need, multi-billion dollar indications including dry AMD, spinal cord injury, and hearing loss.

Key Investment Risks

High reliance on partner Genentech/Roche for the clinical execution and timing of the OpRegen program.
Clinical-stage risk inherent to cell therapies, including potential safety, tolerability, or efficacy failures in human trials.
Persistent operating losses and cash burn typical of development-stage biotech companies.
Complexities in scaling up cGMP-grade manufacturing from pluripotent cell lines.

Thesis Invalidation Triggers

Termination or material negative amendment of the Roche/Genentech collaboration agreement.
Failure of OpRegen to show continued efficacy or acceptable safety in ongoing clinical evaluations.
Severe clinical hold or safety halts imposed by the FDA on the OPC1 program.
Inability to scale up manufacturing processes for new pipeline programs like ILT1 or COR1.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.